Insulin Therapy

Treatment with metformin plus glyburide was not noninferior to insulin alone in preventing large for gestational age infants born from pregnant women with gestational diabetes, according to trial results published in JAMA.

Use of the dual SGLT1/SGLT2 inhibitor sotagliflozin was associated with similar HbA1c reduction for patients with type 1 diabetes using insulin whether or not they also had chronic kidney disease, according to study data.

Five years after receiving a complete response letter from the agency, Lexicon Pharmaceuticals brought sotagliflozin back before an FDA advisory panel to seek an indication to treat patients with type 1 diabetes and chronic kidney disease.

More than one in five adults in the U.S. with type 1 diabetes also have chronic kidney disease, according to findings from a brief report published in Diabetes Care.

ORLANDO — Adults with type 2 diabetes experienced a reduction in HbA1c within 3 months of starting continuous glucose monitoring, regardless of insulin therapy, a presenter reported at the American Diabetes Association Scientific Sessions.

Maternal and paternal metformin use during conception did not increase the risk for adverse pregnancy outcomes, two studies in Annals of Internal Medicine showed.

NEW ORLEANS — A consensus statement on managing diabetic ketoacidosis and hyperosmolar hyperglycemic state for adults with diabetes focuses on preventing recurrence and providing people with the tools to maintain glycemic control.

The 2024 American Diabetes Association Standards of Care put an emphasis on getting continuous glucose monitoring into the hands of more people with diabetes.

In 1999, the FDA approved the Medtronic MiniMed as the first continuous glucose monitor for people with diabetes. In the 25 years since that approval, use of diabetes technology has gradually increased.